First gabapentin for veterinary use launched by Avert Saúde Animal

Decrise® is a gabapentin-based medication specially developed for the behavioral management of felines

A Avert® Animal Health, Biolab's veterinary division, announces the launch of Decrise®, the first gabapentin registered by the Ministry of Agriculture and Livestock (MAPA) for veterinary use in Brazil, developed especially for the behavioral management of felines.

The product was officially presented during the WSAVA 2025 (World Small Animal Veterinary Association Congress), the world's largest veterinary medicine congress, held in Rio de Janeiro, and is the result of active and continuous listening to veterinarians from all over the country.

Decrise® is the answer to a recurring demand from professionals: a safe, practical and targeted solution to the specific challenges related to cat behavior.

With this new product, Avert Saúde Animal reaffirms its role as a partner for veterinarians, focused on developing products that really make a difference to the health and well-being of animals.

Check out the article via the link: First gabapentin for veterinary use launched by Avert Saúde Animal